Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.

Period	fcf
2018-12-31	-$4.60M
2019-12-31	-$6.80M
2020-12-31	-$11.34M
2021-12-31	-$21.78M
2022-12-31	-$19.61M
2023-12-31	-$15.70M
2024-12-31	-$1.54M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TLSA	$1.29	+2.38%	0.14M
3
4
5

Tiziana Life Sciences Ltd (TLSA) Free Cash Flow

Free Cash Flow Data

Get Tiziana Life Sciences Ltd Data in Excel

More TLSA Financial Data